Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Rafael De La Barrera et al.|The Journal of Infectious Diseases|2020Cited by 24
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael Koren, Kayvon Modjarrad, O.S. Adedeji et al.|The Lancet Infectious Diseases|2023Cited by 23
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Alexander C. Schmidt, Rafael De La Barrera et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 17
Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I StudyClemente Díaz, Stephen J. Thomas, Leyi Lin et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 15
Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccineYifan Li, Morgane Rolland, Thembi Mdluli et al.|EBioMedicine|2023Cited by 8